Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

计划入组 200 人 · 首次发布于 2024 年 3 月 15 日

Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults with PKP2 Mutation-associated ARVC

计划入组 15 人 · 首次发布于 2024 年 1 月 29 日

A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

计划入组 9 人 · 首次发布于 2023 年 6 月 2 日

cardiomyopathy program

Adeno-associated virus based cardiomyopathy gene therapies (Nuevocor)

small molecule (oral, Duchenne muscular dystrophy associated cardiomyopathy)

Associated Capital

United States

Associated Medical Supplies Ltd

Canada

Associated Clinicians of East Texas, PLLC

United States

Lexeo Therapeutics Reports Promising Phase I/II Data for Gene Therapy LX2020 in Rare Heart Disease

FDA Grants RMAT Designation to Tenaya's TN-401 Gene Therapy for PKP2-Associated ARVC

Rocket Pharmaceuticals Cuts 30% of Workforce, Refocuses on Cardiovascular Gene Therapies